Genetic variation in metallothionein and metal-regulatory transcription factor 1 in relation to urinary cadmium, copper, and zinc

Toxicology and Applied Pharmacology

Volumn 289, Issue 3, 2015, Pages 381-388

  Adams, Scott V ^a   Barrick, Brian ^b   Christopher, Emily P ^a   Shafer, Martin M ^c   Makar, Karen W ^a   Song, Xiaoling ^a   Lampe, Johanna W ^a   Vilchis, Hugo ^b   Ulery, April ^b   Newcomb, Polly A ^a  

^a USA   (United States)

^b NEW MEXICO STATE UNIVERSITY   (United States)

^c WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

Author keywords

Cadmium; Copper; Metal regulatory transcription factor 1; Metallothionein; Zinc

Indexed keywords

CADMIUM; COPPER; CREATININE; DNA; METAL REGULATORY TRANSCRIPTION FACTOR 1; METAL REGULATORY TRANSCRIPTION FACTOR 1A; METAL REGULATORY TRANSCRIPTION FACTOR 1B; METALLOTHIONEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ZINC; DNA BINDING PROTEIN; TRANSCRIPTION FACTOR MTF-1;

ADULT; AGED; ALLELE; ARTICLE; BODY MASS; CADMIUM URINE LEVEL; CHROMOSOME 16; CONTROLLED STUDY; COPPER URINE LEVEL; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DNA EXTRACTION; FEMALE; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MEDICAL HISTORY; PREVALENCE; SALIVA LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; URINALYSIS; URINE LEVEL; ZINC URINE LEVEL; GENETICS; MALE; MIDDLE AGED; URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CADMIUM; CHROMOSOMES, HUMAN, PAIR 16; COPPER; DNA; DNA-BINDING PROTEINS; FEMALE; GENOTYPE; HUMANS; MALE; METALLOTHIONEIN; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSCRIPTION FACTORS; ZINC;

EID: 84947726001     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.10.024     Document Type: Article

References (54)

1. Abraham J.E., Maranian M.J., Spiteri I., Russell R., Ingle S., Luccarini C., et al. Saliva samples are a viable alternative to blood samples as a source of DNA for high throughput genotyping. BMC Med. Genet. 2012, 5:19.
2. Adams S.V., Newcomb P.A. Cadmium blood and urine concentrations as measures of exposure: NHANES 1999-2010. J. Expo. Sci. Environ. Epidemiol. 2014, 24(2):163-170.
3. Akerstrom M., Barregard L., Lundh T., Sallsten G. The relationship between cadmium in kidney and cadmium in urine and blood in an environmentally exposed population. Toxicol. Appl. Pharmacol. 2013, 268(3):286-293.
4. Akerstrom M., Barregard L., Lundh T., Sallsten G. Variability of urinary cadmium excretion in spot urine samples, first morning voids, and 24h urine in a healthy non-smoking population: implications for study design. J. Expo. Sci. Environ. Epidemiol. 2014, 24(2):171-179.
5. Atkinson C., Newton K.M., Bowles E.J., Yong M., Lampe J.W. Demographic, anthropometric, and lifestyle factors and dietary intakes in relation to daidzein-metabolizing phenotypes among premenopausal women in the United States. Am. J. Clin. Nutr. 2008, 87(3):679-687.
6. Atkinson C., Newton K.M., Stanczyk F.Z., Westerlind K.C., Li L., Lampe J.W. Daidzein-metabolizing phenotypes in relation to serum hormones and sex hormone binding globulin, and urinary estrogen metabolites in premenopausal women in the United States. Cancer Causes Control 2008, 19(10):1085-1093.
7. Atkinson C., Newton K.M., Aiello Bowles E.J., Lehman C.D., Stanczyk F.Z., Westerlind K.C., et al. Daidzein-metabolizing phenotypes in relation to mammographic breast density among premenopausal women in the United States. Breast Cancer Res. Treat. 2009, 116(3):587-594.
8. Babula P., Masarik M., Adam V., Eckschlager T., Stiborova M., Trnkova L., et al. Mammalian metallothioneins: properties and functions. Metallomics 2012, 4(8):739-750.
9. Barr D.B., Wilder L.C., Caudill S.P., Gonzalez A.J., Needham L.L., Pirkle J.L. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ. Health Perspect. 2005, 113(2):192-200.
10. Bremner I., Beattie J.H. Metallothionein and the trace minerals. Annu. Rev. Nutr. 1990, 10:63-83.
11. Carlson C.S., Eberle M.A., Rieder M.J., Yi Q., Kruglyak L., Nickerson D.A. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet. 2004, 74(1):106-120.
12. Carrasco J., Adlard P., Cotman C., Quintana A., Penkowa M., Xu F., et al. Metallothionein-I and -III expression in animal models of Alzheimer disease. Neuroscience 2006, 143(4):911-922.
13. Chen H.I., Chiu Y.W., Hsu Y.K., Li W.F., Chen Y.C., Chuang H.Y. The association of metallothionein-4 gene polymorphism and renal function in long-term lead-exposed workers. Biol. Trace Elem. Res. 2010, 137(1):55-62.
14. Chen X., Lei L., Tian L., Zhu G., Jin T. Bone mineral density and polymorphisms in metallothionein 1A and 2A in a Chinese population exposed to cadmium. Sci. Total Environ. 2012, 423:12-17.
15. Forma E., Krzeslak A., Wilkosz J., Jozwiak P., Szymczyk A., Rozanski W., et al. Metallothionein 2A genetic polymorphisms and risk of prostate cancer in a Polish population. Cancer Genet. 2012, 205(9):432-435.
16. Giacconi R., Cipriano C., Muti E., Costarelli L., Maurizio C., Saba V., et al. Novel-209A/G MT2A polymorphism in old patients with type 2 diabetes and atherosclerosis: relationship with inflammation (IL-6) and zinc. Biogerontology 2005, 6(6):407-413.
17. Giacconi R., Muti E., Malavolta M., Cipriano C., Costarelli L., Bernardini G., et al. The +838 C/G MT2A polymorphism, metals, and the inflammatory/immune response in carotid artery stenosis in elderly people. Molecular medicine (Cambridge. Mass 2007, 13(7-8):388-395.
18. Goulding H., Jasani B., Pereira H., Reid A., Galea M., Bell J.A., et al. Metallothionein expression in human breast cancer. Br. J. Cancer 1995, 72(4):968-972.
19. Gunier R.B., Horn-Ross P.L., Canchola A.J., Duffy C.N., Reynolds P., Hertz A., et al. Determinants and within-person variability of urinary cadmium concentrations among women in northern California. Environ. Health Perspect. 2013, 121(6):643-649.
20. Hamer D.H. Metallothionein. Annu. Rev. Biochem. 1986, 55:913-951.
21. Harvey L.J., Ashton K., Hooper L., Casgrain A., Fairweather-Tait S.J. Methods of assessment of copper status in humans: a systematic review. Am. J. Clin. Nutr. 2009, 89(6):2009S-2024S.
22. Hayashi Y., Hashizume T., Wakida K., Satoh M., Uchida Y., Watabe K., et al. Association between metallothionein genes polymorphisms and sporadic amyotrophic lateral sclerosis in a Japanese population. Amyotroph. Lateral Scler. 2006, 7(1):22-26.
23. Isani G., Carpene E. Metallothioneins, unconventional proteins from unconventional animals: a long journey from nematodes to mammals. Biomolecules 2014, 4(2):435-457.
24. Jiang H., Daniels P.J., Andrews G.K. Putative zinc-sensing zinc fingers of metal-response element-binding transcription factor-1 stabilize a metal-dependent chromatin complex on the endogenous metallothionein-I promoter. J. Biol. Chem. 2003, 278(32):30394-30402.
25. Kayaalti Z., Mergen G., Soylemezoglu T. Effect of metallothionein core promoter region polymorphism on cadmium, zinc and copper levels in autopsy kidney tissues from a Turkish population. Toxicol. Appl. Pharmacol. 2010, 245(2):252-255.
26. Kayaalti Z., Aliyev V., Soylemezoglu T. The potential effect of metallothionein 2A-5A/G single nucleotide polymorphism on blood cadmium, lead, zinc and copper levels. Toxicol. Appl. Pharmacol. 2011, 256(1):1-7.
27. Kelley S.L., Basu A., Teicher B.A., Hacker M.P., Hamer D.H., Lazo J.S. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988, 241(4874):1813-1815.
28. Kim H.G., Kim J.Y., Han E.H., Hwang Y.P., Choi J.H., Park B.H., et al. Metallothionein-2A overexpression increases the expression of matrix metalloproteinase-9 and invasion of breast cancer cells. FEBS Lett. 2011, 585(2):421-428.
29. Kita K., Miura N., Yoshida M., Yamazaki K., Ohkubo T., Imai Y., et al. Potential effect on cellular response to cadmium of a single-nucleotide A→G polymorphism in the promoter of the human gene for metallothionein IIA. Hum. Genet. 2006, 120(4):553-560.
30. Klaassen C.D., Liu J. Role of metallothionein in cadmium-induced hepatotoxicity and nephrotoxicity. Drug Metab. Rev. 1997, 29(1-2):79-102.
31. Kosoy R., Nassir R., Tian C., White P.A., Butler L.M., Silva G., et al. Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum. Mutat. 2009, 30(1):69-78.
32. Krzeslak A., Forma E., Jozwiak P., Szymczyk A., Smolarz B., Romanowicz-Makowska H., et al. Metallothionein 2A genetic polymorphisms and risk of ductal breast cancer. Clin. Exp. Med. 2012.
33. Krzeslak A., Forma E., Chwatko G., Jozwiak P., Szymczyk A., Wilkosz J., et al. Effect of metallothionein 2A gene polymorphism on allele-specific gene expression and metal content in prostate cancer. Toxicol. Appl. Pharmacol. 2013, 268(3):278-285.
34. Lauwerys R., Roels H., Regniers M., Buchet J.P., Bernard A., Goret A. Significance of cadmium concentration in blood and in urine in workers exposed to cadmium. Environ. Res. 1979, 20(2):375-391.
35. Lei L., Chang X., Rentschler G., Tian L., Zhu G., Chen X., et al. A polymorphism in metallothionein 1A (MT1A) is associated with cadmium-related excretion of urinary beta 2-microglobulin. Toxicol. Appl. Pharmacol. 2012, 265(3):373-379.
36. Lowe N.M., Fekete K., Decsi T. Methods of assessment of zinc status in humans: a systematic review. Am. J. Clin. Nutr. 2009, 89(6):2040S-2051S.
37. Luo Y., Xu Y., Bao Q., Ding Z., Zhu C., Huang Z.X., et al. The molecular mechanism for human metallothionein-3 to protect against the neuronal cytotoxicity of Abeta(1-42) with Cu ions. J. Biol. Inorg. Chem. 2013, 18(1):39-47.
38. McElroy J.A., Bryda E.C., McKay S.D., Schnabel R.D., Taylor J.F. Genetic variation at a metallothionein 2A promoter single-nucleotide polymorphism in white and black females in Midwestern United States. J. Toxic. Environ. Health A 2010, 73(19):1283-1287.
39. Palmiter R.D. Regulation of metallothionein genes by heavy metals appears to be mediated by a zinc-sensitive inhibitor that interacts with a constitutively active transcription factor, MTF-1. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(4):1219-1223.
40. Palmiter R.D. The elusive function of metallothioneins. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(15):8428-8430.
41. Raudenska M., Gumulec J., Podlaha O., Sztalmachova M., Babula P., Eckschlager T., et al. Metallothionein polymorphisms in pathological processes. Metallomics 2014, 6(1):55-68.
42. Rentschler G., Kippler M., Axmon A., Raqib R., Ekstrom E.C., Skerfving S., et al. Polymorphisms in iron homeostasis genes and urinary cadmium concentrations among nonsmoking women in Argentina and Bangladesh. Environ. Health Perspect. 2013, 121(4):467-472. 472e461-467.
43. Rentschler G., Kippler M., Axmon A., Raqib R., Skerfving S., Vahter M., et al. Cadmium concentrations in human blood and urine are associated with polymorphisms in zinc transporter genes. Metallomics 2014.
44. Sabolic I., Breljak D., Skarica M., Herak-Kramberger C.M. Role of metallothionein in cadmium traffic and toxicity in kidneys and other mammalian organs. Biometals 2010, 23(5):897-926.
45. Shen R., Fan J.B., Campbell D., Chang W., Chen J., Doucet D., et al. High-throughput SNP genotyping on universal bead arrays. Mutat. Res. 2005, 573(1-2):70-82.
46. Sims H.I., Chirn G.W., Marr M.T. Single nucleotide in the MTF-1 binding site can determine metal-specific transcription activation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(41):16516-16521.
47. Starska K., Krzeslak A., Forma E., Olszewski J., Lewy-Trenda I., Osuch-Wojcikiewicz E., et al. Genetic polymorphism of metallothionein 2A and risk of laryngeal cancer in a Polish population. Med. Oncol. 2014, 31(7):75.
48. Thorisson G.A., Smith A.V., Krishnan L., Stein L.D. The International HapMap Project Web site. Genome Res. 2005, 15(11):1592-1593.
49. Troadec M.B., Ward D.M., Lo E., Kaplan J., De Domenico I. Induction of FPN1 transcription by MTF-1 reveals a role for ferroportin in transition metal efflux. Blood 2010, 116(22):4657-4664.
50. Vasak M., Meloni G. Chemistry and biology of mammalian metallothioneins. J. Biol. Inorg. Chem. 2011, 16(7):1067-1078.
51. Wang Y., Goodrich J.M., Gillespie B., Werner R., Basu N., Franzblau A. An investigation of modifying effects of metallothionein single-nucleotide polymorphisms on the association between mercury exposure and biomarker levels. Environ. Health Perspect. 2012, 120(4):530-534.
52. Yang L., Li H., Yu T., Zhao H., Cherian M.G., Cai L., et al. Polymorphisms in metallothionein-1 and -2 genes associated with the risk of type 2 diabetes mellitus and its complications. Am. J. Physiol. Endocrinol. Metab. 2008, 294(5):E987-E992.
53. Yong M., Schwartz S.M., Atkinson C., Makar K.W., Thomas S.S., Newton K.M., et al. Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States. Cancer Epidemiol. Biomark. Prev. 2010, 19(2):537-546.
54. Zavras A.I., Yoon A.J., Chen M.K., Lin C.W., Yang S.F. Metallothionein-1 genotypes in the risk of oral squamous cell carcinoma. Ann. Surg. Oncol. 2010, 18(5):1478-1483.